A team from Redbiotec used GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system to develop the process. The technology has been effectively applied to both in-house and external co-development programs
Redbiotec uses proprietary rePAX® co-expression technology for the efficient generation of multi-component virus-like particles and other protein assemblies.
More articles on GE Healthcare:
GE Healthcare Sees Slight Profit Increase in Q2
Electronic Data Interchange Market to Reach $1.7B by 2018
Hospitals Buying Integrated EMR Solutions for MU Attestatio
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
